NeuroScientific Biopharmaceuticals Ltd. has been informed by the Human Research Ethics Committee (HREC) it rejected the Company's planned Phase I Clinical Trial for EmtinBTM. In making its decision, HREC determined that at this stage the supporting documentation did not sufficiently address the risk-benefit profile to justify the conduct of the planned Phase I Clinical Trial. The HREC decision to not approve the Phase I Clinical Trial was unexpected and the Company is seeking clarification on the rationale for the decision to determine what steps can be taken to proceed with the Phase I Clinical Trial.
NeuroScientific Biopharmaceuticals Limited
Equities
NSB
AU0000012973
Biotechnology & Medical Research
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.052 AUD | +8.33% | 0.00% | +18.18% |
1st Jan change | Capi. | |
---|---|---|
+18.18% | 4.53M | |
+1.51% | 42.75B | |
+48.15% | 41.61B | |
+8.57% | 41.34B | |
-12.36% | 26.59B | |
+8.92% | 25.49B | |
-25.13% | 18.12B | |
+29.17% | 12.24B | |
-3.12% | 11.76B | |
+6.35% | 11B |
- Stock Market
- Equities
- NSB Stock
- News NeuroScientific Biopharmaceuticals Limited
- Neuroscientific Biopharmaceuticals Ltd. Announces HREC Decision to Not Approve Phase I Clinical Trial